Goldman Sachs analyst Matthew Sykes lowered the firm’s price target on Thermo Fisher (TMO) to $610 from $670 but keeps a Buy rating on the shares after its Q1 results. The company saw strength in the quarter from bioproduction, Pharma services, and research & safety market, but weakness within their US and China academic and government exposure, the analyst tells investors in a research note. Margin and EPS guide were also reduced to reflect the updated headwinds and FX impact, though Thermo Fisher is working to mitigate Tariff headwinds through flexible manufacturing and pricing, the firm added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher price target lowered to $600 from $625 at Leerink
- Positive Outlook for Thermo Fisher Amid Tariff Challenges and Cost Mitigation Strategies
- Thermo Fisher sees Q2 adjusted EPS $5.20-$5.25, consensus $5.73
- Morning Movers: GE Vernova jumps following first quarter results
- Thermo Fisher cuts FY25 adjusted EPS view to $21.76-$22.84 from $23.10-$23.50
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue